- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02791243
Photosensitization Study in Androgenetic Alopecia
May 17, 2017 updated by: Polichem S.A.
A Within-subject, Randomized, Evaluator-blinded, Vehicle-controlled Study to Assess the Photosensitization Potential of Finasteride Cutaneous Solution(P-3074) in Human Subjects
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Healthy male volunteers, drawn from the general population, will be treated with P-3074 solution, placebo vehicle control and 0.9% sodium chloride USP (negative control) by using 6 induction applications on the back area and Ultraviolet A (UVA)/Ultraviolet B (UVB) irradiations during the 3 week induction period, a 10 day rest period, and a challenge phase of a 24-hour patch application, UVA and UVB irradiation followed by evaluation of photosensitization over the subsequent 72 hours.
Study Type
Interventional
Enrollment (Actual)
58
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Essex
-
Chelmsford,, Essex, United Kingdom, CM2 6UA
- Princeton Consumer Research Inc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Males aged 18 to 65.
- Good general health, as assessed by verbal medical history and brief physical examination of the skin.
- Fitzpatrick Skin Type I-IV, determined by interview at screening.
- Willing to use a double-barrier methods (for example, a condom or a diaphragm plus spermicide) during sexual intercourse with a female partner while participating in the study.
- Male subjects will need to confirm method and length of time for method of birth control for female partners.
- Fully informed of the risks of entering the study and willing to provide written consent to enter the study.
- Willing to follow study rules, which include: no sun exposure (for example, no swimming, sunbathing, or tanning beds), avoidance of activities that would cause excessive sweating, no use of lotions, creams, or oils on the back area
- Must be willing not to change current brand of personal care products such as soaps, body washes, laundry detergent, body sprays, body spritzes, etc. while participating on the study.
Exclusion Criteria:
- MED ≤ 2.5 SED for Fitzpatrick Skin Types I and II or MED ≤ 4.0 SED for Fitzpatrick Skin Types III and IV
- Type I Insulin-dependent diabetes
- Mastectomy for cancer involving removal of lymph nodes draining the test site.
- Clinically significant skin diseases which may contraindicate participation, including psoriasis, eczema, atopic dermatitis, and active skin cancer.
- Use of any photosensitizing medications or supplements, such as but not limited to sulfa drugs, tetracyclines, phenothiazines, thiazides, antiemetics and St. John's Wort.
- Any medical conditions caused or affected by sunlight (UV), such as but not limited to solar urticarial and polymorphous light eruptions.
- Active immunologic disorders.
- Routine use of anti-inflammatory, immunosuppressive or antihistamine medications (81 mg aspirin is acceptable).
- Participation in a patch test or soap chamber test within the past 4 weeks.
- History of significant sensitivity or allergy to adhesive bandages, tapes, etc.
- Use of finasteride (oral and/or topical), within 6 months prior to the screening visit.
- Contraindications to finasteride therapy or intolerance of finasteride.
- History of sensitivity to skin solution products.
- Hair, tattoos, pigmentation, scars, moles or other conditions at the areas to be patched that may interfere with patch application, tolerability, or postapplication evaluations.
- Participation in a clinical trial or receipt of an investigational medication within 4 weeks of the study.
- Current treatment with allergy injections.
- History of severe asthma.
- Chronic or active liver disease [alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5x upper limit of normal (ULN)]
- Neutrophils < 1500 cells/mm3
- Clinically significant chronic illness, which could place the subject at increased risk during participation or result in inappropriate dermal response during the study in the opinion of the Investigator.
- History of alcohol or drug abuse within 1 year of the study.
- Any condition the Investigator believes would interfere with the evaluation of the subject, or may put the subject at undue risk.
- Judged by the investigator to be unsuitable for any reason.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Finasteride 0.25%
approximately 0.2 ml of P-3074 (0.25% finasteride)
|
Cutaneous solution of finasteride 0.25%
Other Names:
|
Placebo Comparator: Placebo for Finasteride 0.25%
approximately 0.2 ml of the vehicle cutaneous solution
|
vehicle cutaneous solution of P-3074
Other Names:
|
Other: Negative Control
approximately 0.2 ml of 0.9% aqueous NaCl
|
0.9% aqueous NaCl
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Potential for induction of photosensitization
Time Frame: from day 4 to day 42
|
from day 4 to day 42
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Michael Carr, MD, Princeton Consumer Research Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 9, 2016
Primary Completion (Actual)
June 1, 2016
Study Completion (Actual)
June 27, 2016
Study Registration Dates
First Submitted
June 1, 2016
First Submitted That Met QC Criteria
June 1, 2016
First Posted (Estimate)
June 6, 2016
Study Record Updates
Last Update Posted (Actual)
May 18, 2017
Last Update Submitted That Met QC Criteria
May 17, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Pathological Conditions, Anatomical
- Hypotrichosis
- Hair Diseases
- Alopecia
- Alopecia Areata
- Photosensitivity Disorders
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Urological Agents
- Enzyme Inhibitors
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- 5-alpha Reductase Inhibitors
- Finasteride
Other Study ID Numbers
- PM1542
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Androgenetic Alopecia
-
University of FloridaWithdrawnFemale Androgenetic AlopeciaUnited States
-
Suzhou Kintor Pharmaceutical Inc,Completed
-
King Edward Medical UniversityCompletedCombination of SVF and PRP for Androgenetic AlopeciaPakistan
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Hope Medicine (Nanjing) Co., LtdRecruitingAndrogenetic AlopeciaChina
-
Indonesia UniversityRecruiting
-
Cassiopea SpAICON Clinical Research; Canfield Scientific Inc.; Ergomed PLC; Pharmapace IncRecruitingAlopecia, AndrogeneticGermany, United States, Poland
-
University of ArizonaTransdermal Cap, Inc.Not yet recruitingAndrogenetic Alopecia
-
Gregory L Smith, MD, MPHRecruitingAndrogenetic AlopeciaUnited States
-
Indonesia UniversityCompletedAndrogenetic AlopeciaIndonesia
Clinical Trials on Finasteride 0.25%
-
Polichem S.A.CompletedAlopecia, AndrogeneticBelgium, Germany, Hungary, Russian Federation, Spain
-
GlaxoSmithKlineCompletedAndrogenetic AlopeciaJapan, Argentina, Peru, Philippines, Taiwan, Mexico, Chile, Russian Federation, Thailand
-
Elorac, Inc.Completed
-
EMSRecruitingAndrogenetic AlopeciaBrazil
-
Hospices Civils de LyonUnknown
-
Andrew J. Armstrong, MDCompletedProstate CancerUnited States
-
Iran University of Medical SciencesFiruzgar hospital affiliated to Iran University of Medical SciencesCompletedIdiopathic Hirsutism
-
CancerCare ManitobaTerminatedNon-small Cell Lung CancerCanada
-
Novartis PharmaceuticalsCompletedTreatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome PatientsAustria, Switzerland
-
PfizerCompletedTick-borne EncephalitisAustria, Germany, Poland